Juno is just one part of Celgene's master plan
Seattle biotech Juno Therapeutics' (Nasdaq: JUNO) new partner in the immunotherapy game isn't just interested in treatments for cancer.
New Jersey biopharmaceutical company Celgene Corp. (Nasdaq: CELG) on Tuesday announced it will acquire San Diego-based autoimmune disease treatment company Receptos for $7.2 billion, about $232 per share.
The deal is expected to close in the third quarter.
That pile of cash almost makes Celgene's recent $1 billion deal with Juno—the largest upfront payment for…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Annie Zak Source Type: news
More News: Autoimmune Disease | Biotechnology | Cancer | Cancer & Oncology | Health | Health Management | Immunotherapy | Pharmaceuticals